FDA Panel Skeptical of New OxyContin Formula May 6, 2008
News Summary
Drugmaker Purdue Pharma says that it has made the painkiller OxyContin harder to abuse by adding a plastic-like coating to the pills, but a Food and Drug Administration (FDA) advisory panel said that more testing is needed before the drug can be brought to market, the Associated Press reported May 5.
The FDA typically follows the advice of its advisory panels, although the agency isn't legally bound to do so. "What we heard from the committee was that they have a lot of concern that the formulation had not been adequately evaluated," said Curtis Rosebraugh of the FDA's drug-evaluation office.
The opiate OxyContin has become a popular drug of abuse during the past decade, earning the moniker "hillbilly heroin." Users typically crush the pills to defeat the time-release formula, then snort or inject the powder. The FDA asked its advisory panel to review the latest version of the drug to help determine whether it should be marketed as tamper-resistant, among other concerns.
COMMENTS ON THIS ARTICLE: